On Nov. 7, 2023, the Federal Trade Commission (FTC) announced it is disputing the listing of more than 100 patents in the Food and Drug Administration’s (FDA) “Approved Drug Products.
Anders Olsen and colleagues explore patenting on insulin products by the Federal Drug Agency (FDA) and the impact on market exclusivity and drug prices.
Today, the Federal Trade Commission (FTC) challenged more than 100 patents held by manufacturers of brand-name asthma inhalers, epinephrine autoinjectors, and…
Fucking finally. I’ve been somewhat critical of the glaring failures of this FTC, which has been something of a mess, seemingly spending more time on questionable academic theories, rather than focusing on all sorts of obvious low-hanging fruit, clearly within its authority to protect consumers. So, it was nice a few months ago to see…